FDA regulations require that an
advertisement that makes claims about a prescription drug include a
"fair balance" of information about the benefits and risks of the
advertised product, in terms of both content and presentation (21
CFR 202.1(e)(5)(ii)). In past research FDA has focused primarily on
the risk component of the risk-benefit ratio. In the interest of
thoroughly exploring the issue of fair balance, however, the
presentation of effectiveness, or benefit, information is equally
important.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.